#biomarker targeting

[idontmindifuforgetme]

In hs one night before I went to college literally decided to go into the medical field because I was thinking about people with Alzheimer and it made me sad

Anon why are you so me!! To be clear I’ve wanted to be a doctor my whole life, and neurosurgery has def been a dream of mine for a minute, but yeah the interest in Alzheimer’s is a direct result of scoring my neurodegenerative diseases internship. It’s all just so fuckin sad. The longitudinal study I’m helping with is literally purely observational, bc there’s absolutely nothing that can be done about dementia aside from mitigating it. Rly struggling to reconcile how interesting it all it to how depressing it is to watch people fade away

[newsepick]

Frailty linked to diminished quality of life in cancer and transplant survivors

A research paper published in *Aging* examines the prevalence of frailty in breast cancer and hematopoietic cell transplant survivors, highlighting its correlation with long-term diminished physical performance and quality of life. Conducted by researchers from the University of Minnesota, Columbia University, and Amgen, the study reveals a significant association between frailty and the aging biomarker p16INK4a. The findings emphasize the urgent need for targeted interventions, including senolytic trials, to address frailty and improve the overall wellbeing of these survivor populations

[trendingreportz]

Genomics Market - Forecast(2024 - 2030)

Global Genomic Market Overview:

A genome is the genetic material of an organism. It includes both the genes and the noncoding DNA, as well as mitochondrial DNA and chloroplast DNA. The study of genomes is called genomics. The genomics market is gaining traction owing to its applications in various fields of study such as intragenomic phenomenon including epistasis, pleiotropy, heterosis, and other interactions between loci and alleles within the genome. In this era of medical and life science innovations shaping itself as an inevitable uptake for sustainability of mankind, the genomic research is poised for exponential growth owing to imperative genetic innovations feeding off it. Abundant potential has driven this arcade to reach a staggering market size of $16 billion - $16.5 billion as of 2018, and the demand is estimated to increment at formidable CAGR of 9.2% to 10.2% during the forecast period of 2019 to 2025.

Request Sample

Global Genomic Market Outlook:

Genomics is extensively employed in healthcare, agriculture, biotechnology, DNA sequencing, and diagnostics. In the healthcare segment, genomics is used for the development of vaccines and drugs. This segment leads the application vertical and is growing with a CAGR of 10.1%-10.7 % through to 2025. Genomics plays a significant part in diagnosis of several genetic disorders. It has an ample scope in personalized medication as it can advocate a medical management constructed on the genetic face of a person with the help of clinical data and AI.  It is also applied in synthetic biology and bioengineering. Genomics research in agriculture is hired for plant breeding and genetics to cultivate crop production. The understanding of gene function and the accessibility of genomic maps along with an enhanced understanding of genetic variant will aid the plant breeders to identify the traits and then manipulate those traits to obtain a high yield. All these factors affecting the enormous medical and agricultural sector are all set to stroke the genomics market with abundant demand.

Inquiry Before Buying

Global Genomic Market Growth Drivers:

As per the National Center for Biotechnology Information, U.S, the progression in oncology (study and treatment of tumor) expenses is forecast to rise 7%–10% annually throughout 2020, with universal oncology cost exceeding $150 billion[1]. As per the WHO, cancer is a leading cause of death worldwide, accounting for an estimated 9.6 million deaths in 2018[2]. And the total annual economic cost of cancer at the initial period of this decade was estimated at approximately $1.16 trillion. Thus the application of genomics in exploring cell-free circulating DNA by several R&D sectors as a potential biomarker for cancers is driving the market towards exponential growth. The genomics market with its current potential displays all the necessary traits it can adapt in the coming years to divert a huge chunk of traffic and revenue from the omnipresent cancer diagnostics.

As per the Food and Agriculture Organization of United Nations, between 1960 and 1990 the arable land increased by 1.5 billion ha, and in the recent past decades the elevation recorded is just 155 million ha[3]. With decreasing arable floor and the increasing global population augmenting the demand for food by 70% (by 2050), obtaining a high yield is a major trend in the agricultural sector. Genomics market is all set to capitalize on this unprecedented demand scenario. Genomics supplements the understanding of gene function and the accessibility of genomic maps along with an enhanced understanding of genetic variant, thus aiding the plant breeders to identify the traits and then manipulate those traits to obtain a high yield.

After an acute analysis of the regional insights of the global genomics market, North America is revealed to hold 39% to 40% of the entire global market size as of 2018. Such dominance can be attributed to several aspects such as cumulative investment on research by federal administrations, growing patient awareness, and accessibility of urbane healthcare facilities.

Schedule a Call

Global Genomics Market Players Perspective:

Some of other key players profiled in this IndustryARC business intelligence report are Beckton Dickson, Synthetic Genomics Inc. (SGI) ,Cepheid, Inc., Affymetrix, Inc., Bio-Rad Laboratories, Inc., Agilent Technologies, GE Healthcare, Illumina, Inc., Danaher Corporation,F. Hoffmann-La Roche, QIAGEN, Thermo Fisher Scientific and PacBio (Pacific Biosciences of California). Majority of the companies mentioned are situated in North America augmenting the regional affluence in the global market.

Global Genomics Market Trends:

High overload owing to a wide range of reagents and consumables has propelled companies into approving different policies to endure in the market and stay ahead of the curve.

For instance, in January 2017, BD launched Precise WTA Reagents for precise and guileless quantification of hereditary data form single cell analysis. Moreover, in July 2016, SGI-DNA entered into a distribution agreement with VWR International, an American company involved in the distribution of research laboratory products, with over 1,200,000 items to more than 250,000 customers in North America and Europe.

Genomics Market Research Scope

The base year of the study is 2018, with forecast done up to 2025. The study presents a thorough analysis of the competitive landscape, taking into account the market shares of the leading companies. It also provides information on unit shipments. These provide the key market participants with the necessary business intelligence and help them understand the future of the Genomics Market. The assessment includes the forecast, an overview of the competitive structure, the market shares of the competitors, as well as the market trends, market demands, market drivers, market challenges, and product analysis. The market drivers and restraints have been assessed to fathom their impact over the forecast period. This report further identifies the key opportunities for growth while also detailing the key challenges and possible threats. The key areas of focus include the types of equipment in the Genomics Market, and their specific applications in different phases of industrial operations.

Buy Now

Genomics Market Report: Industry Coverage

Types of Solutions Genomics Market:

By Product Types- Microarray chip, Sequencers.

By Application- Genotyping, SNP analysis.

By End-User- Anthropology, Diagnostics.

The Genomics Market report also analyzes the major geographic regions for the market as well as the major countries for the market in these regions. The regions and countries covered in the study include:

North America: The U.S., Canada, Mexico

South America: Brazil, Venezuela, Argentina, Ecuador, Peru, Colombia, Costa Rica

Europe: The U.K., Germany, Italy, France, The Netherlands, Belgium, Spain, Denmark

APAC: China, Japan, Australia, South Korea, India, Taiwan, Malaysia, Hong Kong

Middle East and Africa: Israel, South Africa, Saudi Arabia

[onlinecancerguide]

How Are Biomarkers Used in Cancer Diagnosis & Treatment?

Biomarkers are biological molecules that provide valuable insights into cancer diagnosis, prognosis, and treatment. They help identify cancer risks, guide treatment choices, and monitor disease progression.

[expopeak]

Annual Immuno-Oncology Summit 2024

[gauricmi]

Personalized Approaches to Cutaneous Squamous Cell Carcinoma Treatment: Targeting Tumor Diversity

Cutaneous Squamous Cell Carcinoma (cSCC) is a heterogeneous disease characterized by diverse clinical and molecular features. Personalized treatment approaches that take into account the unique characteristics of individual tumors have emerged as a promising strategy to improve treatment outcomes and patient survival.

Understanding Cutaneous Squamous Cell Carcinoma: Cutaneous Squamous Cell Carcinoma (cSCC) is a type of skin cancer that arises from the malignant transformation of squamous cells in the epidermis or its appendages. It encompasses a spectrum of disease presentations, ranging from localized lesions to metastatic tumors with varying clinical behaviors.

Tumor Heterogeneity and Molecular Subtypes: Cutaneous Squamous Cell Carcinoma (cSCC) exhibits considerable heterogeneity at the molecular level, with distinct genetic alterations and signaling pathways driving tumor progression and metastasis. Molecular subtyping studies have identified different subgroups of cSCC tumors based on their genomic profiles, providing insights into tumor diversity and potential therapeutic targets.

Precision Medicine in cSCC Treatment: Precision medicine approaches aim to tailor treatment strategies to the specific molecular characteristics of individual tumors, allowing for more targeted and effective therapies. By identifying actionable mutations or biomarkers, clinicians can select therapies that are most likely to benefit patients while minimizing the risk of treatment-related toxicities.

Genomic Profiling and Biomarker Identification: Advances in genomic sequencing technologies have enabled comprehensive profiling of cSCC tumors, revealing recurrent mutations in genes involved in cell cycle regulation, DNA repair, and immune evasion. Biomarker identification efforts seek to identify predictive markers of treatment response and prognosis, guiding treatment decisions in personalized medicine.

Get More Insights On This Topic: Cutaneous Squamous Cell Carcinoma

[reasonsforhope]

"A medical technology company in Australia is aiming for a world-first: it wants to launch a blood test for endometriosis (sometimes called 'endo' for short) within the first half of this year [2025].

In a recent peer-reviewed trial, its novel test proved 99.7 percent accurate at distinguishing severe cases of endometriosis from patients without the disease but with similar symptoms.

Even in the early stages of the disease, when blood markers may be harder to pick out, the test's accuracy remained over 85 percent.

The company behind the patent, Proteomics International, says it is currently adapting the method "for use in a clinical environment," with a target launch date in Australia for the second quarter of this year [2025].

The test is called PromarkerEndo.

"This advancement marks a significant step toward non-invasive, personalized care for a condition that has long been underserved by current medical approaches," managing director of Proteomics International Richard Lipscombe said in a press release from December 30.

Endometriosis is a common inflammatory disease that occurs when tissue similar to the lining of the uterus grows in other parts of the body, forming lesions. The disease can be very painful, and yet the average patient often suffers debilitating symptoms for up to seven years before they are properly diagnosed.

While there are numerous reasons for such a long delay, symptoms of endometriosis are often highly variable, unpredictable, difficult to measure or describe, and dismissed or overlooked by doctors.

Today, the only definitive way to diagnose endometriosis is via keyhole surgery called a laparoscopy, which is expensive, invasive, and carries risks.

Proteomics International is hoping to change that.

In collaboration with researchers at the University of Melbourne and the Royal Women's Hospital, the company compared the bloodwork data from 749 participants of mostly European descent.

Some had endometriosis and others had symptoms that were similar to endo but without the lesions. All participants had a laparoscopy to confirm the presence or absence of the disease.

Sifting through the bloodwork, researchers ran several different algorithms to figure out which proteins in the blood were best at predicting endometriosis of varying stages.

Building on previous research, a panel of 10 proteins showed a "clear association" with endometriosis.

For years now, scientists have investigated possible blood biomarkers of endometriosis to see if they could differentiate between those who have endo and those who do not. Similar to cancerous tumors, endo lesions can establish their own blood supply, and if cervical cancer can be diagnosed via a blood test, it seemed possible that endometriosis could be, too...

Proteomics International claims patents for PromarkerEndo are "pending in all major jurisdictions," starting first in Australia.

It remains to be seen if the company's blood test lives up to the hype and is approved by the Australian Therapeutic Goods Administration (TGA). But that's not outside the realm of possibility.

In November of 2023, some researchers predicted that a "reliable non-invasive biomarker for endometriosis is highly likely in the coming years."

Perhaps this is the year."

-via ScienceAlert, January 9, 2025

--

Note: As someone with endometriosis, let me say that this is a HUGE deal. The condition is incredibly common, incredibly understudied, and incredibly often dismissed. Massive sexism at work here.

I got very lucky and got diagnosed after about 6 months of chronic pain (and extra extra lucky, because my pain went away with medication). But as the article says, the average time to diagnosis is seven years.

Being able to confirm endometriosis diagnoses/rates without invasive surgery will also lead to huge progress in studying/creating treatments for endo.

And fyi: If you have a period that is so painful that you can't stand up, or have to go home from school/work, or vomit, or anything else debilitating (or if any of those things apply if you forget to take pain meds), that is NOT NORMAL, and you should talk to a competent gynecologist asap.

[cbccindia]

Transforming Cancer Care with Precision Oncology

Cancer Immunotherapy stands as a source of encouragement in the landscape of cancer treatment, offering novel approaches that harness the body’s immune system to combat cancer cells. As conventional treatments like Chemotherapy have limitations and can often cause significant side effects, the emergence of Immunotherapy has sparked a new era in oncology, transforming the way we perceive and manage cancer. Let us delve into the intricacies of Cancer Immunotherapy, exploring its mechanisms, efficacy, and impact on cancer treatment, alongside the invaluable contributions of CBCC India in advancing patient care and wellbeing.

[mysticalpeacenut]

Depixus: Unveiling the Secrets of Life with MAGNA™ Technology

Imagine peering into the nanoscale realm, where delicate biomolecules like proteins and DNA orchestrate the symphony of life. MAGNA™ grants scientists this very ability, allowing them to observe and measure the forces at play in these crucial interactions. This unprecedented level of detail opens a treasure trove of possibilities for understanding the mechanisms of disease and designing targeted therapies.

But MAGNA™’s potential extends far beyond disease research. This versatile platform can also be used to study protein-protein interactions in healthy cells, furthering our understanding of fundamental biological processes. Additionally, it can be employed in drug discovery pipelines, accelerating the identification of promising drug candidates.

The implications of MAGNA™ are truly staggering. This revolutionary technology has the power to transform our understanding of life at its most fundamental level, paving the way for a future of personalized medicine and groundbreaking scientific discoveries. Depixus is at the forefront of this revolution, and with MAGNA™ in hand, they are poised to write a new chapter in the story of human health.

[scichores]

Fascinating Role of Genomics in Drug Discovery and Development

This article dives deep into the significance of genomics in drug discovery and development, highlighting well-known genomic-based drug development services that are driving the future of pharmaceutical therapies. #genomics #drugdiscovery

A scientist using a whole genome DNA sequencer, in order to determine the “DNA fingerprint” of a specific bacterium. Original image sourced from US Government department: Public Health Image Library, Centers for Disease Control and Prevention. Under US law this image is copyright free, please credit the government department whenever you can”. by Centers for Disease Control and Prevention is…

[mindblowingscience]

Novel chemical compounds from a fungus could provide new perspectives for treating colorectal cancer, one of the most common and deadliest cancers worldwide. In the journal Angewandte Chemie, researchers have reported on the isolation and characterization of a previously unknown class of metabolites (terpene-nonadride heterodimers). One of these compounds effectively kills colorectal cancer cells by attacking the enzyme DCTPP1, which thus may serve as a potential biomarker for colorectal cancer and a therapeutic target.

Continue Reading.

[unification]

a while ago i made a post outlining my experience of DXM significantly reducing my POTS symptoms. this happens consistently, whenever i have a flare up. since then i’ve looked into the mechanism of action of DXM and known biomarkers of POTS to see where interactions may occur. Overall, I think that dysregulation of glutamatergic signalling/excitotoxic damage and an increase in NADPH oxidase activity play a significant role in the pathophysiology of POTS. I made a post on neocities where I cover this in depth with references (linked above), but to summarise:

MRI studies have shown evidence of increased glutamate and excitotoxic damage in the brains of long covid patients as well as disrupted blood brain barrier integrity. a significant portion of long covid patients either have/develop POTS or experience orthostatic intolerance. from this you can infer that crossover is likely. as well as this, a range of biomarkers capable of contributing to glutamatergic dysregulation are confirmed in POTS patients. This includes enhanced platelet activation/aggregation, increased pro-inflammatory mediators, elevated growth hormone, decreased serotonin levels, autoantibodies against the nicotinic α3β4 and G-protein-coupled adrenergic A1 receptor. Increased plasma angiotensin II/angiotensin dysregulation has also been identified, which suggests increased activity of NADPH oxidase (leading to endothelial damage by reactive oxygen species).

DXM possesses several mechanisms capable of ameliorating this: • assists in regulating glutamate via suppressing overactivity of glutamatergic signalling as well as inducing uptake and recycling of glutamate from the extracellular space (reducing excitotoxicity) • directly targets NADPH Oxidase/NOX2, allowing for potent antioxidant + anti-inflammatory effects and vascular protection • a range of antiplatelet mechanisms • inhibition of serotonin reuptake

[mariacallous]

Several top scientists charged with overseeing research into disease prevention and cures at the National Institutes of Health (NIH) were notified that they were subject to a reduction in force on Tuesday as part of a devastating purge of federal employees carried out by US Health and Human Services secretary Robert Kennedy Jr., WIRED has learned.

Multiple sources at the NIH, granted anonymity because they were not authorized to talk to the media, confirmed Tuesday afternoon that at least 10 principal investigators who were leading and directing medical research at the agency had been fired. Among them is Dr. Richard Youle, a leading researcher in the field of neurodegenerative disorders previously awarded the Breakthrough Prize in Life Sciences for his groundbreaking research identifying mechanisms behind Parkinson’s disease.

The Breakthrough Prize ceremony, often referred to as the “Oscars of Science,” was last year attended by Elon Musk, whose Department of Government Efficiency (DOGE) has served as the tip of the spear in President Donald Trump’s campaign to eliminate large swaths of the federal workforce.

HHS did not respond to WIRED's questions about the firings of NIH scientists. Vianca Rodriguez, an agency spokesperson, pointed to previous statements by Secretary Kennedy, including plans announced last week to eliminate 1,200 NIH jobs in areas of procurement, human resources, and communications.

Multiple NIH sources tell WIRED the layoffs include—in addition to labor, IT, and human resources personnel—several accomplished senior investigators at the National Institute of Neurological Disorders and Stroke (NINDS), top scientists at the National Institute on Aging, and several researchers noted for their work in HIV, emerging infectious diseases, and child brain and neural disorders.

At an NINDS town hall meeting on Tuesday, leadership at that institute expressed confusion about the cuts, saying they were blindsided by firings of principal investigators, or PIs, who lead research teams. NIH has approximately 1,200 PIs across its 27 centers and institutes. “To get rid of 11 of our senior PIs … we’re hoping that’s a mistake, because we can’t figure out why they would want to do that,” said Walter Koroshetz, director of the NINDS, according to a source present at the meeting.

The labs affected by the layoffs include those involved in clinical trials as well as preclinical studies. It is unclear, NIH staff said, what the plans are for the data they've accumulated or what will happen to patients involved in ongoing trials.

An email sent out Tuesday to more than 2,000 recent college graduates, graduate students, and postdoctoral fellows working at NIH seems to confirm the firings of multiple PIs. “Many of us know someone, directly or indirectly, who received a termination notice today as part of an HHS-wide Reduction in Force,” reads an email by Sharon Milgram, director of NIH’s Office of Intramural Training & Education, which was shared with WIRED.

The NIH supports young researchers through various programs, typically temporary one- or two-years fellowships. These early-career scientists are placed in labs under a PI. In her email, Milgram tells fellows with NIH’s postbaccalaureate, cancer research, and visiting fellows programs whose PI received an RIF notice, “I can assure you that your fellowship appointment is not immediately terminated and that we will work with each of you to explore reassignment options soon.”

An effort is said to be underway by NIH leaders to reverse the firings of the investigators, whose absence, sources say, could paralyze research at the agency into finding targets and biomarkers for drug development and other treatment.

The Trump administration sent out notices to thousands of federal health agency employees Tuesday, including at the NIH, the Food and Drug Administration (FDA), and the Centers for Disease Control and Prevention (CDC).

The NIH, which serves as the world's largest source of funding for research into the causes, prevention, and cure of human disease, was stripped of critical support staff on Tuesday in what Health Secretary Kennedy framed as a shift in his agency's priorities. Roughly a quarter of the agency's staff has been cut since the start of Trump's second term.

In a statement on X, Kennedy called the firings a "difficult moment," while blaming the size of his department's budget. "This overhaul is about realigning HHS with its core mission to stop the chronic disease epidemic and Make America Healthy Again," he said.

A senior scientist at NIH tells WIRED the impact of Tuesday's layoffs was sheer "chaos," with the firings of the lead investigators projected to widely impair and impede diverse ongoing research ranging from mechanisms within cells in the brain to human patients with neurologic conditions.

"It's extremely disruptive to lose the head of a lab," another scientist said. "But this is also disruptive for every single lab that does remain at NIH, because they've removed so much of the administrative support that's necessary for us to function."

On Tuesday, US Senators Bill Cassidy, a Republican from Louisiana, and Bernie Sanders, an independent from Vermont, sent a letter to Kennedy inviting him to an April 10 Senate Health, Education, Labor, and Pensions (HELP) Committee meeting on the HHS reorganization.

During his confirmation process, Kennedy committed to providing quarterly updates to the HELP committee, which Cassidy chairs. “This will be a good opportunity for him to set the record straight,” Cassidy said in a statement, “and speak to the goals, structure and benefits of the proposed reorganization.”

[reasonsforhope]

Researchers from Western and Brown University have made groundbreaking progress towards identifying the root cause and potential therapy for preeclampsia.

The pregnancy complication affects up to eight per cent of pregnancies globally and is the leading cause of maternal and fetal mortality due to premature delivery, complications with the placenta and lack of oxygen.

The research, led by Drs. Kun Ping Lu and Xiao Zhen Zhou at Western, and Drs. Surendra Sharma and Sukanta Jash at Brown, has identified a toxic protein, cis P-tau, in the blood and placenta of preeclampsia patients.

According to the study published in Nature Communications, cis P-tau is a central circulating driver of preeclampsia – a “troublemaker” that plays a major role in causing the deadly complication...

“The root cause of preeclampsia has (so far) remained unknown, and without a known cause there has been no cure. Preterm delivery is the only life-saving measure,” said Lu, professor of biochemistry and oncology at  Schulich School of Medicine & Dentistry...

“Our study identifies cis P-tau as a crucial culprit and biomarker for preeclampsia. It can be used for early diagnosis of the complication and is a crucial therapeutic target,” said Sharma...

Until now, cis P-tau was mainly associated with neurological disorders like Alzheimer’s disease, traumatic brain injuries (TBI) and stroke. This association was discovered by Lu and Zhou in 2015 as a result of their decades of research on the role of tau protein in cancer and Alzheimer’s.

An antibody developed by Zhou in 2012 to target only the toxic protein while leaving its healthy counterpart unscathed is currently undergoing clinical trials in human patients suffering from TBI and Alzheimer’s Disease. The antibody has shown promising results in animal models and human cell cultures in treating the brain conditions.

The researchers were curious whether the same antibody could work as a potential treatment for preeclampsia. Upon testing the antibody in mouse models they found astonishing results.

“In this study, we found the cis P-tau antibody efficiently depleted the toxic protein in the blood and placenta, and corrected all features associated with preeclampsia in mice. Clinical features of preeclampsia, like elevated blood pressure, excessive protein in urine and fetal growth restriction, among others, were eliminated and pregnancy was normal,” said Sharma.

Sharma and his team at Brown have been working on developing an assay for early detection of preeclampsia and therapies to treat the condition. He believes the findings of this study have brought them closer to their goal...

“The results have far-reaching implications. This could revolutionize how we understand and treat a range of conditions, from pregnancy-related issues to brain disorders,” said Lu.

-via India Education Diary, September 22, 2023